Conceivable Life Sciences Secures $50 Million to Transform IVF with AI-Driven Automation
Conceivable Life Sciences has announced the successful completion of a $50 million Series A funding round, marking a significant step forward in the integration of artificial intelligence and advanced robotics into the in vitro fertilization (IVF) sector. The round attracted investment from leading venture firms such as ARTIS Ventures, Stride, and ACME Ventures, underscoring widespread confidence in Conceivable’s vision to revolutionize fertility treatment through technology.
Currently, IVF remains a complex and highly manual process, heavily reliant on the expertise, dexterity, and judgment of clinicians. This dependence on human intervention often results in inconsistent outcomes and variable experiences for families seeking fertility solutions. The financial burden is also substantial—an average IVF cycle in the United States can cost between $12,000 and $25,000, with many patients requiring multiple attempts to achieve success. Beyond monetary costs, individuals must navigate strict medication regimens and ongoing health monitoring, adding emotional and physical stress to an already challenging journey.
Conceivable aims to address these pain points by introducing its proprietary lab platform, Aura. Leveraging AI-powered algorithms integrated with robotic hardware, Aura streamlines key steps in the IVF workflow—from dish and sperm preparation to egg identification, fertilization, and incubation. This holistic approach seeks to enhance precision and consistency across the entire process, reducing the likelihood of error and improving outcomes for patients.
Initial studies using Aura have been promising; the platform contributed to the birth of 18 healthy babies. Building on this success, Conceivable is currently conducting a larger clinical trial involving nearly 120 participants, scheduled for completion by year’s end. The company plans to launch Aura commercially early next year, using its new funding to accelerate product development and expand access for families seeking fertility care.
Dr. Alejandro Chavez-Badiola, reproductive endocrinologist and co-founder of Conceivable Life Sciences, emphasized the importance of technology in improving patient outcomes. He noted that while his career in fertility medicine has been deeply rewarding, Conceivable’s mission is to bring greater consistency and reliability to IVF procedures through innovation. “Our goal is to reduce uncertainty and unpredictability inherent in manual processes,” Dr. Chavez-Badiola stated. “By making precision a core aspect of IVF with Aura, we hope to support families at every stage of their journey.”
Competitive Landscape and Growing Demand for Advanced IVF Solutions
The pursuit of AI-driven solutions within the IVF space reflects broader industry trends toward automation and digital health. Nova IVF recently introduced an AI-powered embryo assessment tool designed to improve selection accuracy. SpOvum Technologies is developing novel methods for sperm injection into eggs using advanced robotics. Alongside these innovations are adjunctive technologies that support families throughout their fertility journey—such as ovulation monitoring apps, wearable devices for body temperature regulation, and holistic fertility trackers—all aimed at empowering patients with more data-driven insights.
Conceivable differentiates itself by offering a comprehensive platform that addresses every step of the IVF workflow rather than focusing on isolated point solutions. This approach aligns with rising demand for integrated fertility services: research projects that the global fertility market will reach nearly $87 billion by 2034. Furthermore, corporate support for employee fertility benefits is on the rise; utilization rates are expected to grow by 7% through the decade, with nearly 40% of large employers now providing such benefits.
As technological innovation continues to shape the future of reproductive medicine, Conceivable Life Sciences stands at the forefront—working to make IVF safer, more efficient, and more accessible for families across America.
YOU MAY ALSO LIKE
Why Caesarean Births Are on the Rise Worldwide
Cannabis Use May Quadruple Risk of Type 2 Diabetes, Large Study Suggests
How Budget Cuts Threaten America’s Cancer-Research System
